Breast Cancer Therapeutics on Rise with Latest Innovations!

1
Breast Cancer Therapeutics in Asia-Pacific
Markets to 2021 
Published on 04 February, 2016 Single
User Price 4995 No of Pages 171
The report focuses on global major leading
industry players with information such as company
profiles, product picture and specifications,
sales, market share and contact information.
Whats more, the Breast Cancer Therapeutics in
Asia-Pacific Markets to 2021 development trends
and marketing channels are analyzed.
2
Summary Breast cancer, a malignant neoplasm, is
the second-most common cancer and the most common
cancer in women worldwide, accounting for 16 of
all female cancers, making the disease
exceedingly prevalent. In the past, breast cancer
occurred less in women in Asia than women in
Western countries. However, recent studies show
that breast cancer is being diagnosed more
frequently in women living in Asia, especially
among younger women.
3
There have been wide-reaching changes in the
breast cancer market over the past four decades,
particularly in relation to the usage of targeted
therapies, which has increased significantly. The
marketed products landscape comprises a wide
range of treatment options, including hormonal
therapies, chemotherapies, combination therapies
and targeted therapies. The market is set to be
driven by a number of new approvals for drugs and
an increased uptake of premium targeted
therapies. Nevertheless, significant unmet need
remains for products that can improve overall
survival rate, time to disease progression, and
overall response.
Click Here To Check Complete Report
4
Scope The current breast cancer market contains
novel products, including Perjeta, a targeted
therapy Kadcyla, a human antibody-drug
conjugate and Halaven, a novel chemotherapeutic
agent. - What are the competitive advantages of
the existing novel drugs? - Are these targeted
therapies used to the same magnitude in all the
countries assessed? - What are the factors
contributing to the uptake of these drugs in each
country? With over 700 active pipeline molecules,
most of the investigational drug candidates are
being evaluated for the first-line or second-line
treatment of advanced-stage breast cancer,
featuring new combination therapies, targeted
therapies, and promising immunotherapies, as well
as chemotherapy drug candidates.
5

• Analysis of clinical trials since 2006 identified
  that the failure rates of breast cancer molecules
  were highest in Phase II (41), with the overall
  attrition rate for breast cancer in development
  being 61.
• - How do failure rates vary by product stage of
  development, molecule type, and mechanism of
  action?
• - How do other factors, such as average trial
  duration and trial size, influence the costs and
  risks associated with product development?
• Over the 2014-2021 period, the value of the
  Asia-Pacific markets for breast cancer
  therapeutics is expected to increase at a
  compound annual growth rate of 8.5, from 1.9
  billion to over 3.4 billion.
• - Which markets make the most significant
  contribution to the current market size?
• - What are the epidemiology trends in these
  markets?

Download Sample Brochure
6
Reasons to buy This report will enable you to -
- Understand the clinical context of breast
cancer by considering symptoms, etiology,
pathophysiology, epidemiology, diagnosis, and
treatment options - Identify the therapeutic
strategies, products, and companies that dominate
the current marketed products landscape and
recognize gaps and areas of unmet need - Identify
key pipeline trends in molecule type,
administration route, mechanism of action, and
novelty - Consider market opportunities and
potential risks by examining trends in breast
cancer clinical trial size, duration, and failure
rate by stage of development, molecule type, and
mechanism of action
7

• - Recognize the late-stage pipeline molecules
  that have demonstrated strong therapeutic
  potential in breast cancer by examining clinical
  trial data and multi-scenario product forecast
  projections
• - Compare treatment usage patterns, annual
  therapy costs, and market growth projections for
  the US, Canada, the UK, France, Germany, Italy,
  Spain and Japan
• - Discover trends in licensing and co-development
  deals concerning breast cancer products and
  identify the major strategic consolidations that
  have shaped the commercial landscape

Make an Inquiry Before Buying
8
Key questions answered in this report  What
will the market size be in 2020 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors? You can request one free
hour of our analysts time when you purchase this
market report. Details are provided within the
report.
9
Breast Cancer Therapeutics in Asia-Pacific
Markets to 2021
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Breast Cancer Therapeutics in Asia-Pacific
Markets to 2021 and future opportunities are
provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Breast Cancer
Therapeutics in Asia-Pacific Markets to 2021